Anglia Ruskin Research Online (ARRO)
Browse

Determining clinically important differences in health-related quality of life in older patients with cancer undergoing chemotherapy or surgery

Download (43.41 kB)
journal contribution
posted on 2023-08-30, 16:33 authored by Chantal Quinten, Cindy Kenis, Lore Decoster, Philip R. Debruyne, Inge De Groof, Christian Focan, Frank Cornélis, Vincent Verschaeve, Christian Bachmann, Dominique Bron, Sylvie Luce, Gwenaëlle Debugne, Heidi Van den Bulck, Jean-Charles Goeminne, Abdelbari Baitar, Katrien Geboers, Benedicte Petit, Christine Langenaeken, Ruud Van Rijswijk, Pol Specenier, Guy Jerusalem, Jean-Philippe Praet, Katherine Vandenborre, Michelle Lycke, Johan Flamaing, Koen Milisen, Jean-Pierre Lobelle, Hans Wildiers
PURPOSE: Using the EORTC Global Health Status (GHS) scale, we aimed to determine minimal clinically important differences (MCID) in health-related quality of life (HRQOL) changes for older cancer patients with a geriatric risk profile, as defined by the geriatric 8 (G8) health screening tool, undergoing treatment. Simultaneously, we assessed baseline patient characteristics prognostic for HRQOL changes. METHODS: Our analysis included 1424 (G8 ≤ 14) older patients with cancer scheduled to receive chemotherapy (n = 683) or surgery (n = 741). Anchor-based methods, linking the GHS score to clinical indicators, were used to determine MCID between baseline and follow-up at 3 months. A threshold of 0.2 standard deviation (SD) was used to exclude MCID estimates too small for interpretation. Logistic regressions analysed baseline patient characteristics prognostic for HRQOL changes. RESULTS: The 15-item Geriatric Depression Scale (GDS15), Visual Analogue Scale (VAS) for Fatigue and ECOG Performance Status (PS) were selected as clinical anchors. In the surgery group, MCID estimates for improvement and deterioration were ECOG PS (5*, 11*), GDS15 (5*, 2) and VAS Fatigue (3, 9*). In the chemotherapy group, MCID estimates for improvement and deterioration were ECOG PS (8*, 7*), GDS15 (5, 4) and VAS Fatigue (5, 5*). Estimates with * were > 0.2 SD threshold. Patients experiencing pain or malnutrition (surgery group) or fatigue (chemotherapy group) at baseline showed a significantly stable or improved HRQOL (p < 0.05) after their treatment. CONCLUSION: The reported MCID for improvement and deterioration depended on the anchor used and treatment received. The estimates can be used to evaluate significant changes in HRQOL and to determine sample sizes in clinical trials.

History

Refereed

  • Yes

Volume

28

Issue number

3

Page range

663-676

Publication title

Quality of Life Research

ISSN

1573-2649

Publisher

Springer

File version

  • Accepted version

Language

  • eng

Legacy posted date

2019-09-11

Legacy creation date

2019-09-11

Legacy Faculty/School/Department

Faculty of Health, Education, Medicine & Social Care

Usage metrics

    ARU Outputs

    Categories

    No categories selected

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC